Article Details

EMA panel recommends extending indication for Roche's cancer therapy Tecentriq | Seeking Alpha

Retrieved on: 2022-04-22 21:17:45

Tags for this article:

Click the tags to see associated articles and topics

EMA panel recommends extending indication for Roche's cancer therapy Tecentriq | Seeking Alpha. View article details on HISWAI: https://seekingalpha.com/news/3825821-ema-panel-recommends-extending-indication-for-roches-cancer-therapy-tecentriq

Excerpt

Tecentriq, developed by Roche unit Genentech, got a marketing authorization valid throughout the EU on Sept. 21, 2017.

Article found on: seekingalpha.com

View Original Article

This article is found inside other Hiswai user's workspaces. To start your own collection, sign up for free.

Sign Up